{
    "root": "e9157663-1515-4ba3-83b5-1622cf6f0f99",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Prograf",
    "value": "20230825",
    "ingredients": [
        {
            "name": "TACROLIMUS",
            "code": "WM0HAQ4WNM"
        },
        {
            "name": "PEG-60 HYDROGENATED CASTOR OIL",
            "code": "02NG325BQG"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        }
    ],
    "indications": "prograf calcineurin-inhibitor immunosuppressant indicated prophylaxis organ rejection adult pediatric patients receiving allogeneic liver , kidney , heart , lung transplants , combination immunosuppressants . ( 1.1 )",
    "contraindications": "• intravenous ( iv ) recommended patients tolerate oral formulations ( capsules suspension ) . ( 2.1 , 2.2 ) • administer capsules suspension consistently without food . ( 2.1 ) • therapeutic monitoring recommended . ( 2.1 , 2.6 ) • avoid eating grapefruit drinking grapefruit juice . ( 2.1 ) • adjustments african-american patients ( 2.2 ) , hepatic renal impaired . ( 2.4 , 2.5 ) • complete dosing information , full prescribing information . adult patient population initial oral ( formulation ) whole blood trough concentration range kidney transplant azathioprine 0.2 mg/kg/day capsules , divided two doses , every 12 hours month 1-3 : 7-20 ng/ml month 4-12 : 5-15 ng/ml mmf/il-2 receptor antagonist 0.1 mg/kg/day capsules , divided two doses , every 12 hours month 1-12 : 4-11 ng/ml liver transplant corticosteroids 0.1-0.15 mg/kg/day capsules , divided two doses , every 12 hours month 1-12 : 5-20 ng/ml heart transplant azathioprine mmf 0.075 mg/kg/day capsules , divided two doses , every 12 hours month 1-3 : 10-20 ng/ml month ≥ 4 : 5-15 ng/ml lung transplant azathioprine mmf 0.075 mg/kg/day patients cystic fibrosis may require higher doses due lower bioavailability . capsules , divided two doses , every 12 hours month 1-3 : 10-15 ng/ml month 4-12 : 8-12 ng/ml pediatric patient population initial oral ( formulation ) whole blood trough concentration range kidney transplant 0.3 mg/kg/day capsules oral suspension , divided two doses , every 12 hours month 1-12 : 5-20 ng/ml liver transplant 0.15-0.2 mg/kg/day capsules 0.2 mg/kg/day oral suspension , divided two doses , every 12 hours month 1-12 : 5-20 ng/ml heart transplant 0.3 mg/kg/day dose 0.1 mg/kg/day antibody induction treatment administered . capsules oral suspension , divided two doses , every 12 hours month 1-12 : 5-20 ng/ml lung transplant 0.3 mg/kg/day , capsules oral suspension , divided two doses , every 12 hours weeks 1-2 : 10-20 ng/ml week 2 month 12 : 10-15 ng/ml mmf= mycophenolate mofetil",
    "warningsAndPrecautions": null,
    "adverseReactions": "prograf contraindicated patients hypersensitivity tacrolimus . prograf injection contraindicated patients hypersensitivity hco-60 ( polyoxyl 60 hydrogenated castor oil ) . hypersensitivity symptoms reported include dyspnea , rash , pruritus , acute respiratory distress syndrome [ ( 6 ) ] .",
    "indications_original": "PROGRAF is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. ( 1.1 )",
    "contraindications_original": "• Intravenous (IV) use recommended for patients who cannot tolerate oral formulations (capsules or suspension). ( 2.1 , 2.2 ) • Administer capsules or suspension consistently with or without food. ( 2.1 ) • Therapeutic drug monitoring is recommended. ( 2.1 , 2.6 ) • Avoid eating grapefruit or drinking grapefruit juice. ( 2.1 ) • See dosage adjustments for African-American patients ( 2.2 ), hepatic and renal impaired. ( 2.4 , 2.5 ) • For complete dosing information, see Full Prescribing Information. ADULT Patient Population Initial Oral Dosage (formulation) Whole Blood Trough Concentration Range Kidney Transplant With azathioprine 0.2 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-3: 7-20 ng/mL Month 4-12: 5-15 ng/mL With MMF/IL-2 receptor antagonist 0.1 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-12: 4-11 ng/mL Liver Transplant With corticosteroids only 0.1-0.15 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-12: 5-20 ng/mL Heart Transplant With azathioprine or MMF 0.075 mg/kg/day capsules, divided in two doses, every 12 hours Month 1-3: 10-20 ng/mL Month ≥ 4: 5-15 ng/mL Lung Transplant With azathioprine or MMF 0.075 mg/kg/day Patients with cystic fibrosis may require higher doses due to lower bioavailability. capsules, divided in two doses, every 12 hours Month 1-3: 10-15 ng/mL Month 4-12: 8-12 ng/mL PEDIATRIC Patient Population Initial Oral Dosage (formulation) Whole Blood Trough Concentration Range Kidney Transplant 0.3 mg/kg/day capsules or oral suspension, divided in two doses, every 12 hours Month 1-12: 5-20 ng/mL Liver Transplant 0.15-0.2 mg/kg/day capsules or 0.2 mg/kg/day oral suspension, divided in two doses, every 12 hours Month 1-12: 5-20 ng/mL Heart Transplant 0.3 mg/kg/day Dose at 0.1 mg/kg/day if antibody induction treatment is administered. capsules or oral suspension, divided in two doses, every 12 hours Month 1-12: 5-20 ng/mL Lung Transplant 0.3 mg/kg/day , capsules or oral suspension, divided in two doses, every 12 hours Weeks 1-2: 10-20 ng/mL Week 2 to Month 12: 10-15 ng/mL MMF= Mycophenolate mofetil",
    "adverseReactions_original": "PROGRAF is contraindicated in patients with a hypersensitivity to tacrolimus. PROGRAF injection is contraindicated in patients with a hypersensitivity to HCO-60 (polyoxyl 60 hydrogenated castor oil). Hypersensitivity symptoms reported include dyspnea, rash, pruritus, and acute respiratory distress syndrome [see Adverse Reactions (6)]."
}